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Abstract
We present an integrated valuation model for diseases that pose some chance of death.
The model extends the standard one-period value-of-statistical-life model to three
health prospects: healthy, ill, and dead. We derive willingness-to-pay values for preven-
tion e orts that reduce a disease’s incidence rate as well as for treatments that lower the
corresponding health deterioration and mortality rates. We find that the demand value
of prevention always exceeds that of treatment. People often overweight small risks and
underweight large ones. We use the rank dependent utility framework to explore how
the demand for prevention and treatment alters when people evaluate probabilities in a
non-linear manner. For incidence and mortality rates associated with common types of
cancers, the inverse-S shaped probability weighting found in experimental studies leads
to a significant increment in the demand values of both treatment and prevention.
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1 Introduction
How should government expenditure on health be allocated to maximize social welfare? An-
swers to this question require understanding people’s preferences for di erent health inter-
ventions (Fuchs and Zeckhauser 1997). In this paper, we develop a stylized health valuation
framework and apply it to the combat of cancer. Since the 1970s significant progress has
been made in preventing, diagnosing, and treating cancer. However, cancer remains one of
the leading causes of death.1 Some researchers have therefore argued that society spends too
much on the development of new cancer drugs and other treatment methods, and too little
on prevention and diagnosis (Sporn 1996, Chabner and Roberts 2005, Faguet 2005). If that
claim were true, then society would not operate at the production possibility frontier (where
the good to be produced is additional life years for cancer patients) and a Pareto improve-
ment could be achieved by re-allocating resources from R&D to prevention and screening
e orts.
E ciency concerns have been raised against the supply side of fighting cancer, but
similar arguments hold for the demand side as well (Bosworth et al. 2010). Consider empirical
studies that suggest people value a reduction in the risk of dying from cancer more than they
value a reduction in the risk of dying from other causes (Hammitt and Liu 2004, Van Houtven
et al. 2008, Viscusi et al. 2013). Such preferences should be reflected in the allocation of
the health budget, as they are essential to health policy assessments; e.g. to quantifying the
social value of the U.S. war on cancer (Lakdawalla et al. 2010).
In this paper, we develop willingness-to-pay (WTP) metrics for prevention-based and
treatment-based health interventions to study value tradeo s between incidence rate, mor-
tality rate, and the life quality of cancer patients. The proposed model extends the standard
economic model of preferences for mortality risk reductions (Jones-Lee 1974, Weinstein et
al. 1980), which spurred the development of the value of statistical life (VSL) metric. In
1In 2012 cancer caused approximately 8.2 million deaths worldwide, making it the leading cause of death
ahead of coronary heart diseases (Ferlay et al. 2015).
2
the spirit of Gerking et al. (2014), we presume that disease-induced mortality is conditional
on su ering the disease. Therefore, our model includes three health states: healthy, ill, and
dead. The explicit inclusion of the illness state allows us to identify the relative value of a
gain in life quality when ill (Hammitt 2002).2
While consistent with the standard economic approach of valuing health risks, our
baseline model does not capture that many people have neither a clear understanding of the
risk of developing cancer, nor of the likelihoods of various outcomes of screening tests and
treatment methods (Slovic et al. 2005, Peters et al. 2006). When presented with statistical
information, they tend to overemphasize small probabilities and underemphasize large ones.
This implies an inverse-S shaped probability weighting function (Tversky and Wakker 1995).
As most cancers involve small incidence and large mortality rates, probability weighting may
significantly a ect how people value such risks. In order to address the non-linear weighting
of probabilities, we follow Bleichrodt and Eeckhoudt (2006) and apply the rank dependent
utility (RDU) framework to our model. Calibrations of the RDU version of our model to
U.S. lung and skin cancer rates suggest that non-linear probability weighting significantly
increases the demand value of reductions in both cancer incidence and mortality.
The paper proceeds as follows. In section 2, we introduce the baseline model and
derive the WTP metrics for reductions in the incidence rate, the conditional mortality, and
the health deterioration rate. We compare their relative size assuming real values of these
rates for some types of cancer. In section 3, we replace the linear probability measures of the
expected utility model by non-linear probability weighting and compare the rank dependent
WTP metrics to those derived for the baseline model. Section 4 concludes.
2A previous treatment of these three states by Magat et al. (1996) used a risk-risk tradeo  framework,
but did not examine monetary value-health risk tradeo s.
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2 Baseline model
In this section, we introduce the baseline model of cancer risk valuation and derive WTP
values for a reduction in the incidence rate, the mortality rate and the deterioration of life
quality, respectively. We loosely follow the notation of Bleichrodt et al. (2003).
2.1 Set up
Let an individual derive utility U(W,H) from wealth W and health H. We denote first
(second) derivatives with respect to wealth by the subscript 1 (11) and those with respect
to health by the subscript 2 (22). We make the following conventional assumptions about
U(W,H):
• Non-satiation with respect to money: U1(W,H) > 0;
• Non-satiation with respect to health: U2(W,H) > 0;
• Weak financial risk aversion: U11(W,H) Æ 0;
• Weak health risk aversion: U22(W,H) Æ 0; and
• Correlation a nity: U12(W,H) Ø 0.
The first two assumptions are the usual non-satiation assumptions. The next two assumptions
state that less risk over either health or wealth is preferable to more risk. The last assumption
implies that the marginal utility of wealth does not decrease with better health. In other
words, a healthy person enjoys the benefits of an extra dollar at least as much as an ill
person.3 Viscusi and Evans (1990), Sloan et al. (1998), and more recently Finkelstein et al.
(2013) provide empirical support for this assumption.
Now, consider a target disease that threatens health with probability q = pr(sick).
Without further knowledge about the individual’s pre-condition and genetic constitution,
3Eeckhoudt et al. (2007) propose a straightforward way to empirically test the sign of U12(W,H).
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it is sensible to assume that q equals the population incidence rate of the target disease.
Conditional on falling ill, the individual faces a probability p = pr(death|sick) to die from
the disease. Thus, there are three possible states of the world in our model:
1. Remaining at the current (good) health level HG with probability (1≠ q);
2. Developing the disease and surviving in the reduced (bad) health state HB with prob-
ability q(1≠ p);
3. Dying from the target disease, which implies health HD with probability qp.
Without loss of generality, we will measure health quality on a unit scale so that HG = 1,
HD = 0, and HB = 1 ≠ h, where h < 1 is the health deterioration expected from the non-
fatal outcome of the disease. Each of the above health conditions is associated with a state-
dependent utility function U(W,HG) > U(W,HB) > U(W,HD) satisfying the preferential
order HG º HB º HD, where º indicates strict preferences. More precisely, we assume that
for any given wealth endowment W utility can be normalized to U(W,HG) = 1, U(W,HD) =
0, and 0 < U(W,HB) < 1.
Under the assumptions made so far, U2(W,HB) is unbounded above. Yet, since the
average value of U2(W,H) between HB and HD is U(W,HB)/HB and the average value
between HB and HG is (1≠ U(W,HB))/(1≠HB), we may define an upper bound assuming
that the sign of U22(W,H) does not change between HD and HG. Then, these two values
bound U2(W,HB). If we further assume U22(W,H) < 0, then U(W,HB)/HB > 1 and (1 ≠
U(W,HB))/(1 ≠ HB) < 1. Based on these assumptions, which are common in the health
risk literature, we argue that U2(W,HB) is on the order of 1 and equals 1 i  the individual
is risk neutral with respect to health. With risk aversion, we obtain the following bounds:
(1≠ U(W,HB))/(1≠HB) < U2(W,HB) < U(W,HB)/HB.
Based on the above assumptions, the individual’s expected utility takes the form:
E[U(W,H)] = (1≠ q)U(W,HG) + q[(1≠ p)U(W,HB) + pU(W,HD)]. (1)
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We are interested in how much a representative individual is willing to pay for a reduction in
either the incidence rate q, the conditional mortality rate p, or the health deterioration rate
h associated with a particular (cancer) disease.
Let us first define the compensating variation Cq = C(W,H, ◊q, p, q) as the amount of
money the individual is willing to give up in order to reduce the incidence rate q by the
amount ◊q. By definition, the payment of Cq for the risk reduction ◊q implies indi erence
between the utility level before and after the transfer. Hence,
E[U(W,H)] = (1≠q+◊q)U(W≠Cq, HG)+(q≠◊q)[(1≠p)U(W≠Cq, HB)+pU(W≠Cq, HD)].
(2)
Next, we di erentiate Eq. (2) with respect to the risk reduction ◊q to obtain the first
order condition:
ˆE[U ]
ˆ◊q
= U(W ≠ Cq, HG)≠ [(1≠ p)U(W ≠ Cq, HB) + pU(W ≠ Cq, HD)]≠Ë
(1≠ q + ◊q)ˆUGˆCq
ˆCq
ˆ◊q
≠ (q ≠ ◊q)[(1≠ p)ˆUBˆCq
ˆCq
ˆ◊q
+ pˆUDˆCq
ˆCq
ˆ◊q
]
È
= 0.
(3)
Solving Eq. (3) for ˆCqˆ◊q yields the marginal WTP for reductions in the risk of contracting
the disease:
MWTPq © ˆCqˆ◊q =
U(W≠Cq ,HG)≠[(1≠p)U(W≠Cq ,HB)+pU(W≠Cq ,HD)]
E[U1(W≠Cq ,H)] > 0, (4)
where the numerator equals the gain in expected utility from avoiding the disease and the
denominator is the expected marginal utility of consumption, both evaluated after the pay-
ment of Cq.4 It follows from Eq. (4) that MWTPq increases with both the risk of dying
from the disease (i.e., ˆ2Cqˆ◊qˆp > 0) and the risk of losing more life quality when surviving (i.e.,
ˆ2Cq
ˆ◊qˆh
> 0).
4Notice that Cq goes to zero when the reduction in the incidence of the disease becomes infinitesimally
small. If contracting the disease results in certain death (or a health deterioration that is equally bad), i.e.
p = pr(death|sick) = 1, then (1≠ q) becomes the survival probability and Eq. (4) simplifies to the standard
VSL expression (Jones-Lee 1974; Weinstein et al. 1980). This highlights the close link between our model
and the VSL literature.
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Similarly, we define the compensating variation Cp = C(W,H, ◊p, p, q) for a reduction
in the disease-specific mortality risk p by the amount ◊p. The corresponding marginal WTP
is given by
MWTPp © ˆCpˆ◊p =
q[U(W≠Cp,HB)≠U(W≠Cp,HD)]
E[U1(W≠Cp,H)] > 0, (5)
where the numerator equals the gain in expected utility from reduced cancer mortality and
the denominator is the expected marginal utility of consumption, both evaluated after the
payment of Cp. A higher incidence rate increasesMWTPp (i.e., ˆ
2Cp
ˆ◊pˆq
> 0), while the prospect
of a more painful course of disease may decrease or increase MWTPp depending on whether
or not the e ect of poorer health on the marginal utility of consumption (in the bad health
state) outweighs its beneficial e ect on the total utility of survival (Hammitt 2002).
Lastly, consider the compensating variation Ch = C(W,H, ◊h, p, q) for a reduction in
the severity of the disease by the amount ◊h. The corresponding marginal WTP is given by
MWTPh © ˆChˆ◊h =
q(1≠p)U2(W≠Ch,HB+◊h)
E[U1(W≠Ch,H)] > 0, (6)
where the numerator equals the gain in expected utility due to a less severe form of the
disease. MWTPh rises with increasing risk of contracting the disease (i.e., ˆ
2Ch
ˆ◊hˆq
> 0). This
makes intuitive sense because a higher incidence rate of the disease makes the individual more
likely to benefit from therapies that increase the life quality. In contrast, it is not possible
to sign the e ect of an increment in the mortality rate on the marginal WTP for reductions
in h. A larger risk of dying conditional on being ill reduces the benefit of therapy (i.e. the
numerator), but it simultaneously reduces the expected utility from consumption (i.e. the
denominator). Again, it is an empirical question which of the two opposed e ects is stronger.
We summarize all of the above findings in Result I.
Result I. Health interventions that improve any of the three health dimensions q, p, and h are
valuable. However, the WTP values associated with an improvement in one of the dimensions
are not independent of the other two dimensions. In particular, a higher incidence rate
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increases the WTP for reductions in p and h; a higher conditional mortality rate increases
WTP for reductions in q, but its e ect on the demand value of reductions in h is ambiguous;
a more severe form of the disease increases WTP for reductions in q, but its e ect on the
demand value of reductions in p is again ambiguous.
2.2 Relative value of interventions
Result I indicates that the individual is willing to pay for interventions that ameliorate any
of the three health dimensions. But which one is the most valuable dimension in terms of
demand value? We compare the marginal value of improvements in the three dimensions by
evaluating the WTP metrics (4–6) at the baseline level in order to identify the most e cient
way to allocate a given health budget. That is, we set ◊• = 0 (where • is a placeholder
for q, p, and h) implying C• = 0. Therefore, the three WTP metrics share a common
denominator. The corresponding ratios give us the marginal rate of substitution between
any two dimensions and permit assessing the relative value of prevention vs life quality vs
prolongation of life.
We summarize the comparisons of the dimension-specific marginal WTP metrics in the
following three results.5
Result II. Reductions in q are more valuable than reductions in p i :
MWTPq > MWTPp ¡ 1≠ U(W,HB)
U(W,HB)
> q ≠ p.
Since severe diseases including most forms of cancer are characterized by p∫ q, prevention
is more valuable than treatment for such diseases. This may seem counterintuitive at first
sight. Notice, however, that the numerator in Eq. (5) is scaled by q, implying that it is
ine cient to invest in reducing p if q is small.
5Detailed derivations are relegated to Appendix A.
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Result III. Reductions in h are more valuable than reductions in p i :
MWTPh > MWTPp ¡ (1≠ p)U2(W,HB) > U(W,HB).
We know that U2(W,HB) < U(W,HB)/(1 ≠ h). Substituting this upper bound, we obtain
h > p as a necessary condition for MWTPh > MWTPp. Likewise, we can substitute
the lower bound to obtain (1 ≠ p)/h > U(W,HB)/(1 ≠ U(W,HB)), which is a su cient
condition for MWTPh > MWTPp. One situation in which the latter condition is met is
when U(W,HB) æ 0. In words, if life quality in the bad health state is so low that the
individual is indi erent between staying alive and dying, palliative actions become more
valuable than prolonging life (and further su ering).
Result IV. Reductions in q are typically more valuable than reductions in h. We obtain the
following criterion:
MWTPq > MWTPh ¡ 1≠ (1≠ p)U(W,HB) > q(1≠ p)U2(W,HB).
We again substitute U(W,HB)/(1≠h) for U2(W,HB), yielding the following su ciency condi-
tion forMWTPq > MWTPh : 1≠(1≠p)U(W,HB) > q(1≠p)U(W,HB)/(1≠h). Substituting
the lower bound yields a second condition for MWTPq > MWTPh : 1≠ (1≠ p)U(W,HB) >
q(1 ≠ p)(1 ≠ U(W,HB))/h. These conditions are met if either q or U(W,HB) is su ciently
small, or p is su ciently large—criteria that are commonly associated with cancer diseases.
3 Probability weighting
Results II-IV provide important insights on the relative value of the di erent ways to reduce
the health endpoints associated with the target disease. Yet we have so far ignored that
people often lack a clear understanding of health risks, particularly of the risks posed by
cancer and other dreaded diseases (Peters et al. 2006). A robust finding in experiments on
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risky health decisions is that people overweight small probabilities and underweight large ones
(Lichtenstein et al. 1978, Bleichrodt and Pinto 2000, Abellan-Perpiñan et al. 2009, Attema
et al. 2013). We follow Bleichrodt and Eeckhoudt (2006) and apply the RDU framework to
study the e ect of probability weighting on cancer risk valuation.
The hypothesis of RDU is that any probability measure P is evaluated as if they were
transformed by a weighting function w [P ] such that w [0] = 0, w [1] = 1, w [P ] > P for P
close 0, w [P ] < P for P close to 1, and w [P ] = P at some intermediate value. If w [P ] is
di erentiable, then wÕ > 0 for all P and wÕ > 1 for P in the vicinity of 0 and 1, respectively.6
One particularly popular weighting function is Prelec’s (1998) two-parameter specification
w [P ] = exp(≠—(≠ lnP )–), where the parameter – governs the curvature, which indicates
the patient’s sensitivity to changes in risk, i.e. his ability to discriminate between di erent
risk levels. The parameter — controls the elevation of the weighting function, which expresses
the degree to which the patient is willing to take (health) risks.
Bleichrodt and Eeckhoudt (2006) made this functional choice for two reasons. First,
the Prelec weighting function is continuously di erentiable with:
ˆw [P ]
ˆP
= —–(≠ lnP )
–≠1
P
exp(≠—(≠ lnP )–).
Second, Bleichrodt and Pinto (2000) elicited –ˆ = 0.534 and —ˆ = 1.083 in the health
risk/longevity context. Below, we will use the Bleichrodt-Pinto (BP) calibration of the Pr-
elec weighting function as a benchmark. The model can be calibrated with other probability
weighting functions, however.7 Hence, we emphasize that our results do not depend on the
functional form of w [P ] .
6Any such weighting function displays an inverse S-shaped form (Tversky and Wakker 1995).
7Fehr-Duda and Epper (2012) provide a thorough review of the probability weighting functions in use.
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3.1 WTP metrics under probability weighting
We assume that each probability source is weighted separately to reflect source independence
(Wakker 2010). The individual could, of course, transform the compound lottery of falling
ill and surviving (dying) into a simple lottery. Yet, it seems to us that developing the disease
and dying from the disease are two di erent risks, which the individual is likely to weight
di erently (Armantier and Treich 2016). In any case, the main conclusion drawn from the
analysis of the RDU modeling (Result VIII below) does not depend on this assumption, see
the additional analysis in Appendix C.
The rank-dependent counterpart of the expected utility function (1) is given by
RD[U(W,H)] = w [1≠ q]U(W,HG)+
(1≠ w [1≠ q]) {w [1≠ p]U(W,HB) + (1≠ w [1≠ p])U(W,HD)} .
(7)
Similar to Section 2, we derive WTP metrics for improvements in q, p, and h. In particular,
we can re-write Eq. (7) as
RD[U(W,H)] = w [1≠ q + ◊q]U(W ≠ Cwq , HG)+
(1≠ w [1≠ q + ◊q])
Ó
w [1≠ p]U(W ≠ Cwq , HB) + (1≠ w [1≠ p])U(W ≠ Cwq , HD)
Ô
.
(8)
where Cwq = C(W,H, ◊q, p, q, w[.]) denotes the compensating variation for a reduction in the
incidence rate q of the target disease by the amount ◊q in the presence of probability weighting
by the function w [.]. The corresponding marginal WTP under probability weighting is:
MWTPwq ©
ˆCwq
ˆ◊q
= w
Õ[1≠q+◊q ]{U(W≠Cwq ,HG)≠w[1≠p]U(W≠Cwq ,HB)≠(1≠w[1≠p])U(W≠Cwq ,HD)}
RD[U1(W≠Cwq ,H)] > 0.
(9)
In the same way, we obtain the marginal WTP for the reduction in the disease-specific
mortality rate p:
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MWTPwp ©
ˆCwp
ˆ◊p
= (1≠w[1≠q])w
Õ[1≠p+◊p]{U(W≠Cwp ,HB)≠U(W≠Cwp ,HD)}
RD[U1(W≠Cwp ,H)] > 0,
(10)
and the marginal WTP for the reduction in the health deterioration rate h:
MWTPwh ©
ˆCwh
ˆ◊h
= (1≠w[1≠q])w[1≠p]U2(W≠C
w
h ,HB+◊h)
RD[U1(W≠Cwh ,H)] > 0.
(11)
3.2 Relative value of interventions under probability weighting
Does probability weighting a ect the relative value of one of the intervention channels over
another? We address this question by comparing the marginal value of improvements in the
three health dimensions. We do so by evaluating the WTP metrics (9–11) at the baseline
level (i.e., ◊• = 0). Comparisons of the intervention-specific marginal WTP metrics are
summarized in the following three results.
Result V. Reductions in q are more valuable than reductions in p i :
MWTPwq > MWTP
w
p ¡
wÕ [1≠ q]
(1≠ w [1≠ q])wÕ [1≠ p] + wÕ [1≠ q]w [1≠ p] > U(W,HB).
The LHS of the inequality is under very mild assumptions larger than one, so that even
under probability weighting prevention of cancer is more valuable than treatment. Yet the
condition is more demanding than under expected utility (Result II) as probability weighting
increases the denominator for common values of q, p, and any inverse S-shaped weighting
function w [.].
Result VI. Reductions in h are more valuable than reductions in p i :
MWTPwh > MWTP
w
p ¡ w [1≠ p]U2(W,HB) > wÕ [1≠ p]U(W,HB).
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By substituting U(W,HB)/(1 ≠ h) as the upper bound of U2(W,HB), we obtain h > 1 ≠
w[1≠p]
wÕ[1≠p] as a necessary condition for MWTPwh > MWTPwp . Likewise, if we substitute
(1 ≠ U(W,HB))/h, we obtain the lower bound: w [1≠ p] /(hwÕ [1≠ p]) > U(W,HB)/(1 ≠
U(W,HB)), which is a su cient condition for MWTPwh > MWTPwp . Comparison with
Result III suggests that for commonly observed p-values the condition is more demanding
under probability weighting (with an inverse-S shaped weighting function) than under linear
probabilities; e.g., for the BP calibration we have that 1≠ p < w[1≠p]wÕ[1≠p] ’p > 0.24.
Result VII. Reductions in q are more valuable than reductions in h i :
MWTPwq > MWTP
w
h ¡ 1≠ w [1≠ p]U(W,HB) >
(1≠ w [1≠ q])w [1≠ p]
wÕ [1≠ q] U2(W,HB).
Again, we may substitute U2(W,HB) by U(W,HB)/(1≠h) and by (1≠U(W,HB))/h, yielding
the following two su ciency condition for MWTPwq > MWTPwh :
1≠ w [1≠ p]U(W,HB) > (1≠ w [1≠ q])w [1≠ p]
wÕ [1≠ q]
U(W,HB)
1≠ h ,
and
1≠ w [1≠ p]U(W,HB) > (1≠ w [1≠ q])w [1≠ p]
wÕ [1≠ q]
(1≠ U(W,HB))
h
.
These conditions are met if either q is su ciently small or p is su ciently large or both.
Compared to Result IV, we find that under probability weighting (with an inverse-S shaped
weighting function) the criteria are more demanding than in the baseline model.
3.3 Probability-weighted vs baseline WTP metrics
What is the bias introduced by probability weighting on the WTP metrics for di erent types
of intervention? To address this question, we compare Eqs. (9–11) to the baseline WTP
metrics (4–6). In doing so, we assume again that ◊• = 0 and evaluate the WTP metrics
at the initial levels of q, p, and h. We compare the baseline to probability-weighted WTP
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metrics by examining the following ratios:
µq © MWTP
w
q
MWTPq
= wÕ[1≠ q]1≠ w[1≠ p]U(W,HB)1≠ (1≠ p)U(W,HB)
E[U1(W,H)]
RD[U1(W,H)]
(12)
µp © MWTP
w
p
MWTPp
= (1≠ w[1≠ q])w
Õ[1≠ p]
q
E[U1(W,H)]
RD[U1(W,H)]
, and (13)
µh © MWTP
w
h
MWTPh
= (1≠ w[1≠ q])w[1≠ p]
q(1≠ p)
E[U1(W,H)]
RD[U1(W,H)]
. (14)
Eqs. (12–14) are not very intuitive. In order to draw meaningful conclusions, we
calibrate the model using the BP calibration of the Prelec weighting function and prevailing
incidence and mortality rates for lung and skin cancer in the U.S. According to the latest
estimates of the U.S. National Cancer Institute about 6.6 percent of men and women will be
diagnosed with lung cancer at some point during their lifetime, of which 17.4 percent will
survive five years or more after the diagnosis.8 Based on these statistics we set q = 0.066 and
p = 0.826. Moreover, we normalize the utility functions so that U(W,HG) = 1, U(W,HB) =
1≠ h, U(W,HD) = 0. We vary the health deterioration rate h for lung-cancer survivors from
[0, 1], although both extremes might be somewhat unrealistic.
Panels A-C of Figure 1 show the three WTP ratios, µq, µp and µh, calibrated to U.S.
lung-cancer incidence and mortality rates. Across the range of possible h-values the ratios
are well above unity, implying that probability weighting with the BP calibration leads
to up to five times higher WTP values than those derived under the baseline model. In
Panels D-F of Figure 1, the same WTP ratios are displayed for current U.S. skin-cancer
(melanoma) incidence and mortality rates, which imply p = 0.085, q = 0.021.9 Although the
survival prospects are much better for skin-cancer patients, probability weighting with the
8See http://www.seer.cancer.gov/statfacts.
9Most skin cancer is nonmelanoma, which has very high incidence and very low mortality.
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Figure 1: WTP ratios for lung and skin cancer in the U.S.
Notes: Panels A-C display calibrations with current U.S. lung cancer rates; Panels D-F display calibrations
with current U.S. skin cancer rates; all calibrations are based on Bleichrodt and Pinto (2006). Code for
replicating the calibrations is provided in Appendix D.
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BP calibration leads to up to ten times higher WTP values than those derived under the
baseline model. This motivates our last result.
Result VIII. Under a weighting function w[.] that overweights small probabilities and un-
derweights large ones, probability weighting increases the WTP for interventions that improve
any of the three health dimensions:
MWTPq < MWTP
w
q , MWTPp < MWTP
w
p , andMWTPh < MWTPwh .
4 Conclusion
We have extended the standard VSL model to analyze the economic value of interventions
that reduce either the incidence rate, the conditional mortality rate, or the health deteriora-
tion rate of severe diseases such as cancer. The valuation model we propose suggests that for
commonly observed incidence and mortality rates, social investment into cancer prevention
should have priority over investment into the development of new drugs and other treatments.
In other words, reducing the chance to su er from cancer is more desirable than improving
survival chances. This is not to say that improvements in cancer treatment and detection
methods are worthless, however. Gains in longevity and quality of life are, of course, valuable
to cancer patients (Lakdawalla et al. 2010).
Many people overweight small probabilities such as those implied by cancer incidence
rates, but underweight large probabilities such as those implied by the corresponding mortal-
ity rates. We have therefore employed the RDU framework to explore non-linear probability
weighting in health valuations related to severe diseases.10 We find that the WTP for re-
ductions in any of the three rates—incidence, mortality, and health detoriation—are several
10An upshot of the comparison between EU-based and RDU-based WTP metrics is that the same technique
can be applied to study other factors that might enter the decision maker’s probabilistic reasoning. In
Appendix B, we apply the approach to assess how comorbidity risks a ect the relative valuation of the
di erent intervention channels. Other applications are conceivable.
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times larger than under the linear-in-probabilities assumption of the EU framework. This
further supports the qualitative findings of the baseline model; even if people do not evaluate
health risks using linear probabilities, prevention is more valuable than treatment.
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Appendix A—Detailed Derivations
Derivation of Result II. We insert Eqs. (4–5) and evaluate them at ◊• = 0 to obtain the
equivalence relationship:
MWTPq > MWTPp ¡ U(W,HG)≠ [(1≠ p)U(W,HB) + pU(W,HD)]
E[U1(W,H)]
>
q [U(W,HB)≠ U(W,HD)]
E[U1(W,H)]
.
The RHS can be transformed to:
U(W,HG)≠ U(W,HB)
U(W,HB)≠ U(W,HD) > q ≠ p,
and, assuming U(W,HG) = 1 and U(W,HD) = 0, we obtain Result II.
Derivation of Result III. We insert Eqs. (5–6) and evaluate them at ◊• = 0 to obtain the
equivalence relationship:
MWTPh > MWTPp ¡ q(1≠ p)U2(W,HB)
E[U1(W,H)]
>
q [U(W,HB)≠ U(W,HD)]
E[U1(W,H)]
.
The RHS can be transformed to:
(1≠ p)U2(W,HB) > U(W,HB)≠ U(W,HD).
Next, we assume U(W,HD) = 0 and replace U2(W,HB) by the upper bound U(W,HB)/HB =
U(W,HB)/(1≠ h) derived in Section 2.1:
(1≠ p)U(W,HB)/(1≠ h) > U(W,HB),
based on which we obtain h > p as a necessary condition for MWTPh > MWTPp.
If we instead substitute U2(W,HB) by the lower bound (1 ≠ U(W,HB))/(1 ≠ HB) =
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(1≠ U(W,HB))/h, we obtain:
(1≠ p)(1≠ U(W,HB))/h > U(W,HB),
which yields the su ciency condition for Result III.
Derivation of Result IV. We insert Eqs. (4) and (6) and evaluate them at ◊• = 0 to obtain
the equivalence relationship:
MWTPq > MWTPh ¡ U(W,HG)≠ [(1≠ p)U(W,HB) + pU(W,HD)]
E[U1(W,H)]
>
q(1≠ p)U2(W,HB)
E[U1(W,H)]
.
The RHS can be transformed to:
U(W,HG)≠ (1≠ p)U(W,HB)≠ pU(W,HD) > q(1≠ p)U2(W,HB).
Next, we assume U(W,HG) = 1 and U(W,HD) = 0 and replace U2(W,HB) by the upper
bound U(W,HB)/(1≠ h) derived in Section 2.1 to obtain:
1≠ (1≠ p)U(W,HB) > q(1≠ p)U(W,HB)/(1≠ h),
which is the first su ciency condition for MWTPq > MWTPh. Substituting the lower
bound (1≠ U(W,HB))/h instead, yields the second su ciency condition for Result IV:
1≠ (1≠ p)U(W,HB) > q(1≠ p)(1≠ U(W,HB))/h.
Derivation of Result V. We insert Eqs. (9–10) and evaluate them at ◊• = 0 to obtain the
equivalence relationship:
MWTPwq > MWTP
w
p ¡
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wÕ[1≠q]{U(W,HG)≠w[1≠p]U(W,HB)≠(1≠w[1≠p])U(W,HD)}
RD[U1(W,H)]
>
(1≠w[1≠q])wÕ[1≠p]{U(W,HB)≠U(W,HD)}
RD[U1(W,H)]
.
The RHS can be transformed to:
wÕ[1≠q]{U(W,HG)≠w[1≠p]U(W,HB)≠(1≠w[1≠p])U(W,HD)} > (1≠w[1≠q])wÕ[1≠p]{U(W,HB)≠U(W,HD)}.
Assuming U(W,HG) = 1 and U(W,HD) = 0, this expression simplifies to Result V:
wÕ [1≠ q] {1≠ w [1≠ p]U(W,HB)} > (1≠ w [1≠ q])wÕ [1≠ p]U(W,HB) =
wÕ [1≠ q] > U(W,HB) {(1≠ w [1≠ q])wÕ [1≠ p] + wÕ [1≠ q]w [1≠ p]} =
wÕ[1≠q]
(1≠w[1≠q])wÕ[1≠p]+wÕ[1≠q]w[1≠p] > U(W,HB).
Derivation of Result VI. We insert Eqs. (10–11) and evaluate them at ◊• = 0 to obtain the
equivalence relationship:
MWTPwh > MWTP
w
p ¡
(1≠ w [1≠ q])w [1≠ p]U2(W,HB)
RD[U1(W,H)]
>
(1≠ w [1≠ q])wÕ [1≠ p] {U(W,HB)≠ U(W,HD)}
RD[U1(W,H)]
.
The RHS equals:
(1≠ w [1≠ q])w [1≠ p]U2(W,HB) > (1≠ w [1≠ q])wÕ [1≠ p] {U(W,HB)≠ U(W,HD)} .
Next, we assume U(W,HD) = 0 and replace U2(W,HB) by the upper bound U(W,HB)/(1≠h)
derived in Section 2.1:
(1≠ w [1≠ q])w [1≠ p]U(W,HB)/(1≠ h) > (1≠ w [1≠ q])wÕ [1≠ p]U(W,HB) =
1≠ w[1≠p]wÕ[1≠p] < h,
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yielding the necessary condition for Result VI.
If we instead substitute U2(W,HB) by the lower bound (1≠ U(W,HB))/h, we obtain:
(1≠ w [1≠ q])w [1≠ p] (1≠ U(W,HB))/h > (1≠ w [1≠ q])wÕ [1≠ p]U(W,HB) =
w[1≠p]
wÕ[1≠p]h >
U(W,HB)
1≠U(W,HB) ,
which yields the su ciency condition for Result VI.
Derivation of Result VII.We insert Eqs. (9) and (11) and evaluate them at ◊• = 0 to obtain
the equivalence relationship:
MWTPwq > MWTP
w
h ¡
wÕ[1≠q]{U(W,HG)≠w[1≠p]U(W,HB)≠(1≠w[1≠p])U(W,HD)}
RD[U1(W,H)]
>
(1≠w[1≠q])w[1≠p]U2(W,HB)
RD[U1(W,H)]
.
The RHS equals:
wÕ[1≠q]{U(W,HG)≠w[1≠p]U(W,HB)≠(1≠w[1≠p])U(W,HD)} > (1≠w[1≠q])w[1≠p]U2(W,HB).
Next, we assume U(W,HG) = 1 and U(W,HD) = 0 and replace U2(W,HB) by the upper
bound U(W,HB)/(1≠ h) and the lower bound (1≠ U(W,HB))/h, respectively:14
wÕ[1≠q]{1≠w[1≠p]U(W,HB)} > (1≠w[1≠q])w[1≠p]U(W,HB)/(1≠h) =
1≠w[1≠p]U(W,HB) > (1≠w[1≠q])w[1≠p]wÕ[1≠q]
U(W,HB)
1≠h .
and
wÕ[1≠q]{1≠w[1≠p]U(W,HB)} > (1≠w[1≠q])w[1≠p](1≠U(W,HB))/h =
1≠w[1≠p]U(W,HB) > (1≠w[1≠q])w[1≠p]wÕ[1≠q]
1≠U(W,HB)
h .
These are the su ciency conditions for Result VII.
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Appendix B—Comorbidity risks and WTP
Assume that the individual faces a comorbidity (Bleichrodt et al. 2003; Liu 2004) or other
competing background risk (Eeckhoudt and Hammitt 2001). We introduce a mortality back-
ground risk fi, which can be interpreted either as a specific competing disease or as the
compound risk of dying from any other cause than the target disease.
Consider the extended form of expected utility:
E[Ufi(W,H)] = (1≠ fi)(1≠ q)U(W,HG) + (15)
q[(1≠ fi)(1≠ p)U(W,HB) + (1≠ (1≠ fi)(1≠ p))U(W,HD)].
We derive WTP metrics for improvements in q, p, and h similarly to those in Section 2. In
particular, we re-write Eq. (15) as
E[Ufi(W,H)] = (1≠ fi)(1≠ q + ◊q)U(W ≠ Cfiq , HG) + (16)
(q ≠ ◊q)[(1≠ fi)(1≠ p)U(W ≠ Cfiq , HB) + (1≠ (1≠ fi)(1≠ p))U(W ≠ Cfiq , HD)],
where Cfiq = C(W,H, ◊q, p, q, fi) denotes the compensating variation for a reduction in the
incidence rate q of the target disease by the amount ◊q in the presence of the background
risk fi. The corresponding marginal WTP is:
MWTPfiq ©
ˆCfiq
ˆ◊q
= (1≠fi)U(W≠C
fi
q ,HG)≠[(1≠fi)(1≠p)U(W≠Cfiq ,HB)+(1≠(1≠fi)(1≠p))U(W≠Cfiq ,HD)]
E[Ufi1 (W ≠ Cfiq , H)]
> 0. (17)
In the same way, we obtain the marginal WTP for the reduction in the disease-specific
mortality rate p:
MWTPfip ©
ˆCfip
ˆ◊p
=
q(1≠ fi) #U(W ≠ Cfip , HB)≠ U(W ≠ Cfip , HD)$
E[Ufi1 (W ≠ Cfip , H)]
> 0, (18)
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and the marginal WTP for the reduction in the health deterioration rate h:
MWTPfih ©
ˆCfih
ˆ◊h
= q(1≠ fi)(1≠ p)U2(W ≠ Ch, HB + ◊h)
E[Ufi1 (W ≠ Cfih , H)]
> 0. (19)
Next, we compare Eqs. (17–19) to the baseline WTP metrics given by Eqs. (4–6). We
assume ◊• = 0 and evaluate the ratios of the corresponding WTP metrics at the baseline
levels of q, p, and h:
MWTPq
MWTP fiq
= U(W,HG)≠[(1≠p)U(W,HS)+pU(W,HD)](1≠fi)U(W,HG)≠[(1≠fi)(1≠p)US+(1≠(1≠fi)(1≠p))UD]
(1≠fi)(1≠q) ˆU0ˆW +q[(1≠fi)(1≠p)
ˆUS
ˆW +(1≠(1≠fi)(1≠p))
ˆUD
ˆW ]
(1≠q) ˆU0ˆW +q[(1≠p)
ˆUS
ˆW +p
ˆUD
ˆW ]
=
B≠pUD
B≠ (1≠(1≠fi)(1≠p))(1≠fi) UD
A+q (1≠(1≠fi)(1≠p))(1≠fi)
ˆUD
ˆW
A+qp ˆUDˆW
> 1.
MWTPp
MWTP fip
=
(1≠q) ˆU0ˆW +q[(1≠p)
ˆUS
ˆW +
(1≠(1≠fi)(1≠p))
(1≠fi)
ˆUD
ˆW ]
(1≠q) ˆU0ˆW +q[(1≠p)
ˆUS
ˆW +p
ˆUD
ˆW ]
=
A+q (1≠(1≠fi)(1≠p))(1≠fi)
ˆUD
ˆW
A+qp ˆUDˆW
> 1.
MWTPh
MWTP fih
=
(1≠q) ˆU0ˆW +q[(1≠p)
ˆUS
ˆW +
(1≠(1≠fi)(1≠p))
(1≠fi)
ˆUD
ˆW ]
(1≠q) ˆU0ˆW +q[(1≠p)
ˆUS
ˆW +p
ˆUD
ˆW ]
=
A+q (1≠(1≠fi)(1≠p))(1≠fi)
ˆUD
ˆW
A+qp ˆUDˆW
> 1.
The findings are summarized in the following result.
Result IX. As long as the individual derives marginal utility from leaving a larger bequest
to others, a physical background risk reduces the demand value for improvements in all three
health dimensions:
MWTPq ØMWTP fiq , MWTPp ØMWTP fip , andMWTPh ØMWTP fih .
Similarly to the original why-bother e ect (Eeckhoudt and Hammitt 2001), the inequalities
become strict if the marginal utility of a bequest is larger than zero.
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Appendix D—RDU model for compound probabilities
In case that the individual weights the compound probability of developing cancer and (not)
dying from cancer, the RDU model writes:
RD[U(W,H)] = w [1≠ q + ◊q]U(W ≠ Cwq , HG)+
w [(q ≠ ◊q)(1≠ p)]U(W ≠ Cwq , HB) + w [(q ≠ ◊q)p]U(W ≠ Cwq , HD).
(20)
where Cwq = C(W,H, ◊q, p, q, w[.]) denotes the compensating variation for a reduction in the
incidence rate q of the target disease by the amount ◊q in the presence of probability weighting
by the function w [.]. The corresponding marginal WTP becomes:
MWTPwq ©
ˆCwq
ˆ◊q
= w
Õ[1≠q+◊q ]U(W≠Cwq ,HG)≠{wÕ[(q≠◊q)(1≠p)]U(W≠Cwq ,HB)≠wÕ[(q≠◊q)p]U(W≠Cwq ,HD)}
RD[U1(W≠Cwq ,H)] > 0.
(21)
In the same way, we obtain the marginal WTP for the reduction in the disease-specific
mortality rate p:
MWTPwp ©
ˆCwp
ˆ◊p
= w
Õ[q(1≠p+◊p)]U(W≠Cwp ,HB)≠wÕ[q(p≠◊p)]U(W≠Cwp ,HD)
RD[U1(W≠Cwp ,H)] > 0,
(22)
and the marginal WTP for the reduction in the health deterioration rate h:
MWTPwh ©
ˆCwh
ˆ◊h
= w[q(1≠p)]U2(W≠C
w
h ,HB+◊h)
RD[U1(W≠Cwh ,H)] > 0.
(23)
The thrust of the results V-VIII still holds.
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Appendix E—Code for Replication
The following R code enables replication of Figure 1.
##parametrization based on Bleichrodt and Pinto (2006)
alpha=0.534;beta=1.083
h=seq(0:99)/100;u=1;v=1-h
##Lung cancer calibration, data retrieved from http://seer.cancer.gov/statfacts/html/lungb.html
q=0.066;Q=1-q;p=1-0.174;P=1-p
w_Q=exp(-beta*(-log(Q))^alpha) #weighting function for incidence risk
dw_Q=beta*alpha*(-log(Q))^(alpha-1)*w_Q/Q #marginal weighting function for incidence risk
w_P=exp(-beta*(-log(P))^alpha) #weighting function for mortality risk
dw_P=beta*alpha*(-log(P))^(alpha-1)*w_P/P #marginal weighting function for mortality risk
##Eq. (12) split up in parts
rq_1=dw_Q;rq_2=(u-w_P*v)/(u-P*v);rq_3=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rq=rq_1*rq_2*rq_3
##Panel A of Figure 1
par(mfrow=c(2,3)) #graphic setting
plot(h,rq,main="A - reduction in lung cancer incidence",lwd=2,type="l",cex.main=.95,
xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio"~mu[q]))
##Eq. (13) split up in parts
rp_1=((1-w_Q)*dw_P)/q;rp_2=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rp=rp_1*rp_2
##Panel B of Figure 1
plot(h,rp,main="B - reduction in lung cancer mortality",lwd=2,type="l",cex.main=.95,
xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio"~mu[p]))
##Eq. (14) split up in parts
rh_1=((1-w_Q)*w_P)/(q*P);rh_2=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rh=rh_1*rh_2
##Panel C of Figure 1
plot(h,rh,main="C - reduction in lung-cancer caused health deterioration", lwd=2,type="l",
cex.main=.95,xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio"~mu[h]))
##Skin cancer calibration, data retrieved from http://seer.cancer.gov/statfacts/html/melan.html
q=0.021;Q=1-q; p=1-.915;P=1-p
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w_Q=exp(-beta*(-log(Q))^alpha) #weighting function for incidence risk
dw_Q=beta*alpha*(-log(Q))^(alpha-1)*w_Q/Q #marginal weighting function for incidence risk
w_P=exp(-beta*(-log(P))^alpha) #weighting function for mortality risk
dw_P=beta*alpha*(-log(P))^(alpha-1)*w_P/P #marginal weighting function for mortality risk
##Eq. (12) split up in parts
rq_1=dw_Q;rq_2=(u-w_P*v)/(u-P*v);rq_3=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rq=rq_1*rq_2*rq_3
##Panel D of Figure 1
plot(h,rq,main="D - reduction in skin cancer incidence",lwd=2,type="l",cex.main=.95,
xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio" ~ mu[q]))
##Eq. (13) split up in parts
rp_1=((1-w_Q)*dw_P)/q;rp_2=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rp=rp_1*rp_2
##Panel E of Figure 1
plot(h,rp,main="E - reduction in skin cancer mortality",lwd=2,type="l",
cex.main=.95,xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio"~mu[p]))
##Eq. (14) split up in parts
rh_1=((1-w_Q)*w_P)/(q*P);rh_2=(Q*u+(1-Q)*P*v)/(w_Q*u+(1-w_Q)*w_P*v);rh=rh_1*rh_2
##Panel F of Figure 1
plot(h,rh,main="F - reduction in skin-cancer caused health deterioration", lwd=2,type="l",
cex.main=.95,xlab="Health detoriation rate (h)",ylab=expression("MWTP ratio"~mu[h]))
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